ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rituximab and vasculitis"

  • Abstract Number: 1672 • 2019 ACR/ARP Annual Meeting

    Use of Rituximab for the Treatment of ANCA-Associated Vasculitis in Canada, 2010-2018

    Arielle Mendel1, Simon Carette 2 and Christian Pagnoux 2, 1Mount Sinai Hospital, Toronto, ON, Canada, 2Mount Sinai Hospital and University Health Network, Toronto, ON, Canada

    Background/Purpose: Rituximab (RTX) is an effective therapy for ANCA-Associated Vasculitis (AAV).  The Canadian Vasculitis Research Network (CanVasc) recommends RTX for induction among patients with unacceptable risk…
  • Abstract Number: 904 • 2018 ACR/ARHP Annual Meeting

    Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Results of the Four-Year Study of Rituximab in ANCA-Associated Vasculitis Registry

    John L. Niles1, Peter A. Merkel2, Lester Mertz3, Patricia B. Lehane4, Pooneh Pordeli5 and Félix Erblang6, 1Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 3Rheumatology, Mayo Clinic, Rochester, MN, 4Roche Products Ltd., Welwyn Garden City, United Kingdom, 5Hoffmann-La Roche Ltd., Mississauga, ON, Canada, 6Hoffmann-La Roche Ltd., Basel, Switzerland

    Background/Purpose: Potential therapy-related toxicities are important causes of morbidity in patients with the ANCA-associated vasculitides granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Long-term safety…
  • Abstract Number: 1758 • 2018 ACR/ARHP Annual Meeting

    A 24 Month Analysis of Rituximab Safety and Efficacy in Eosinophilic Granulomatosis with Polyangiitis

    Vítor Teixeira1,2, Aladdin Mohammad1,3 and David Jayne1, 1Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 2Rheumatology Department, CHLN - Santa Maria Hospital, Lisbon Academic Medical Center, Lisbon, Portugal, 3Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) frequently pursues a refractory course leading to high glucocorticoid exposure and toxicity. A previous retrospective study found rituximab (RTX)…
  • Abstract Number: 2743 • 2018 ACR/ARHP Annual Meeting

    Favorable Efficacy of Rituximab in ANCA-Associated Vasculitis Patients with Excessive B Cell Differentiation

    Yusuke Miyazaki1, Shingo Nakayamada1, Satoshi Kubo1, Kazuhisa Nakano1, Shigeru Iwata2, Shunsuke Fukuyo3, Akio Kawabe4 and Yoshiya Tanaka5, 1First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 3University of Occupational and Environmental Health, Japan, Fukuoka, Japan, 4University of Occupational and Environmental Health, Japan, Kitakyusyu, Japan, 5University of Occupational and Environmental Health, Kitakyushu, Japan

    Background/Purpose: B cell depletion by rituximab (RTX)is effective treatment for ANCA-associated vasculitis (AAV). However, the phenotype of peripheral B cells and the selection criteria for…
  • Abstract Number: 18L • 2017 ACR/ARHP Annual Meeting

    Rituximab As Re-Induction Therapy in Relapsing ANCA-Associated Vasculitis

    Rona Smith1, Rachel Jones2, Ulrich Specks3, Carol A McAlear4, Kim Mynard2, Simon Bond2, David Jayne5 and Peter A. Merkel6, 1Department of Medicine, University of Cambridge, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 2Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, 3Mayo Clinic College of Medicine, Rochester, MN, 4University of Pennsylvania, Philadelphia, PA, 5Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 6Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: RITAZAREM (ClinicalTrials.gov: NCT01697267) is an international, randomized, controlled trial comparing rituximab with azathioprine as maintenance therapy after induction of remission with rituximab and glucocorticoids…
  • Abstract Number: 1752 • 2017 ACR/ARHP Annual Meeting

    Pharmacokinetics of Rituximab and Clinical Outcomes in Patients with ANCA-Associated Vasculitis

    Divi Cornec1, Brian Kabat1, John Mills1, Melissa Cheu2, Amber Hummel1, Darrell Schroeder1, Matthew Cascino3, Paul Brunetta3, David Murray1, Melissa Snyder1, Fernando Fervenza1, Gary S. Hoffman4, Cees G.M. Kallenberg5, Carol A. Langford6, Peter A. Merkel7, Paul A. Monach8, Philip Seo9, Robert F. Spiera10, E. William St Clair11, John H. Stone12, David Barnidge1 and Ulrich Specks13, 1Mayo Clinic, Rochester, MN, 2Genentech Inc., South San Francisco, CA, 3Genentech, Inc., South San Francisco, CA, 4Rheumatology, Cleveland Clinic, Cleveland, OH, 5Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 6Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 7University of Pennsylvania, Philadelphia, MN, 8Boston University School of Medicine, Boston, MA, 9Medicine, Johns Hopkins University, Baltimore, MD, 10Rheumatology, Hospital for Special Surgery, New York, NY, 11Rheumatology, Duke University Medical Center, Durham, NC, 12Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 13Mayo Clinic College of Medicine, Rochester, MN

    Background/Purpose: Response to rituximab (RTX) is variable in patients with ANCA-associated vasculitis (AAV), and predictors of treatment efficacy/relapse risk would be useful. Previous studies have…
  • Abstract Number: 1757 • 2017 ACR/ARHP Annual Meeting

    Rituximab for Induction and Maintenance Therapy of Granulomatosis with Polyangiitis: A Single-Center Cohort Study on 114 Patients

    Xavier Puéchal1, Michele Iudici1, Ana Luisa Calich2, Alexandre Vivot3, Benjamin Terrier4, Alexis Regent1, Pascal Cohen4, Claire Le Jeunne4, Luc Mouthon5, Philippe Ravaud6 and Loïc Guillevin for the French Vasculitis Study Group7, 1National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 2Universidade Federal de São Paulo, Hospital São Paulo, São Paulo, Brazil, 3Epidemiology, Hotel Dieu, Paris, France, 4Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, 5Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France, 6Paris Hotel Dieu, Paris, France, 7Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France

    Background/Purpose: Randomized–controlled trials (RCTs) showed rituximab’s (RTX) noninferiority to cyclophosphamide for induction therapy of severe ANCA-associated vasculitides and significantly lower relapse rate than azathioprine maintenance.…
  • Abstract Number: 1759 • 2017 ACR/ARHP Annual Meeting

    Economic Evaluation of Rituximab Versus Azathioprine for Maintenance Treatment of ANCA-Associated Vasculitis. a Prospective, Multicenter Study

    Annalisa Montante1, Alicia Le Bras2, Benjamin Terrier3, Pascal Cohen3, Xavier Puéchal4, Alexandre Karras5, Philippe Ravaud6, Loïc Guillevin7 and Isabelle Durand-Zaleski8, 1UNITÉ DE RECHERCHE ECONOMIQUE, UNIVERSITE PARIS DESCARTES, PARIS, France, 2UNITE DE RECHERCHE ECONOMIQUE, UNIVERSITE PARIS DESCARTES, PARIS, France, 3Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, 4Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, 5Nephrology, HEGP, Paris, France, 6Hôpital Hôtel Dieu, Paris, France, 7Internal medicine, Cochin University Hospital, paris, France, 8UNITE DE RECHERCHE ECONOMIQUE, UNIVERSITE DE PARIS-CRETEIL, PARIS, France

    Background/Purpose: Rituximab was proven to be superior to azathioprine as maintenance therapy for ANCA-associated vasculitides (AAVs) at month 28 of MAINRITSAN-1–trial follow-up. Because of rituximab’s…
  • Abstract Number: 2754 • 2017 ACR/ARHP Annual Meeting

    Comparison of Individually Tailored Vs Systematic Rituximab Regimens to Maintain ANCA-Associated Vasculitis Remissions: Results of a Prospective, Randomized–Controlled, Phase 3 Trial

    Pierre Charles1, Benjamin Terrier2, Elodie Perrodeau3, Pascal Cohen2, Stanislas Faguer4, Antoine Huart5, Mohamed Hamidou6, Christian Agard7, Bernard Bonnotte8, Maxime Samson8, Alexandre Karras9, Noémie Jourde-Chiche10, François Lifermann11, Pierre Gobert12, Catherine Hanrotel-Saliou13, Pascal Godmer14, Nicolas Martin Silva15, Grégory Pugnet16, Marie Matignon17, Olivier Aumaître18, Estibaliz Lazaro19, Xavier Puéchal20, Philippe Ravaud21, Luc Mouthon22 and Loïc Guillevin20, 1Service de Médecine Interne, Hôpital Cochin, Paris, France, 2Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, 3Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 42Service de Néphrologie et Immunologie Clinique, Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France, 5CHU, Toulouse, France, 6Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, 7Internal Medicine Department, Nantes University Hospital, Nantes, France, 8Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 9Nephrology, HEGP, Paris, France, 10Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, 11Dax, Dax, France, 12Nephrology, Centre Hospitalier d'Avignon, Avignon, France, 13Brest, Brest, France, 14Medecine Interne, CH Vannes, Vannes, France, 15Department of Internal Medicine, Caen University Hospital, Caen, France, 16Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, 17Service de Néphrologie, Hôpital Henri-Mondor, Créteil, Créteil, France, 18CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, 19service de médecine interne et maladies infectieuses, CHU de Bordeaux, Pessac, France, 20National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 21Hôpital Hôtel Dieu, Paris, France, 22Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France

    Background/Purpose: Once ANCA-associated vasculitis (AAV) remission was obtained, rituximab (RTX) superiority to azathioprine (AZA) to maintain remission was shown.1 In that study, at month 28,…
  • Abstract Number: 2936 • 2017 ACR/ARHP Annual Meeting

    B-Cell Depletion By Rituximab Affects the Distribution of Effector Th-Cell Subsets in Patients with ANCA Associated Vasculitis

    Wayel H. Abdulahad1, Ulrich Specks2, Theo Bijma3, Deborah J. Phippard4, Fredrick Karnell5, Noha Lim5, John H. Stone6 and Cees G.M. Kallenberg1, 1Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 2Mayo Clinic College of Medicine, Rochester, MN, 3UMCG, Groningen, Netherlands, 43 Bethesda Metro Center,, Suite 400, Bethesda, MD, 5Immune Tolerance Network, Bethesda, MD, 6Rheumatology Unit, Massachusetts General Hospital, Boston, MA

    Background/Purpose: The current study is aimed to assess the effect of B-cell depletion on the distribution of effector T-cell subsets in AAV-patients. Alterations in CD4+…
  • Abstract Number: 16L • 2016 ACR/ARHP Annual Meeting

    Comparison of Systematic Vs Individually Tailored Rituximab Regimen to Maintain ANCA-Associated–Vasculitis Remission: Results of a Prospective, Randomized–Controlled, Phase 3 Trial

    Pierre Charles1, Benjamin Terrier2, Pascal Cohen3, Stanislas Faguer4, Antoine Huart5, Mohamed Hamidou6, Christian Agard7, Bernard Bonnotte8, Maxime Samson8, Alexandre Karras9, Noémie Jourde-Chiche10, François Lifermann11, Pierre Gobert12, Catherine Hanrotel-Saliou13, Pascal Godmer14, Nicolas Martin Silva15, Grégory Pugnet16, Marie Matignon17, Olivier Aumaître18, Estibaliz Lazaro19, Luc Mouthon20, Loïc Guillevin21 and French Vasculitis Study Group, 1Service de Médecine Interne, Hôpital Cochin, Paris, France, 2Internal Medicine, Cochin University Hospital, Paris, France, 3Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, 42Service de Néphrologie et Immunologie Clinique, Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France, 5CHU, Toulouse, France, 6Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, 7Internal Medicine Department, Nantes University Hospital, Nantes, France, 8Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 9Nephrology, HEGP, Paris, France, 10Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, 11CH Dax, Dax, France, 12Nephrology, Centre Hospitalier d'Avignon, Avignon, France, 13CHU Cavale Blanche, Brest, Brest, France, 14CH Vannes, Vannes, France, 15Department of Internal Medicine, Caen University Hospital, Caen, France, 16Service de Médecine Interne, CHU de Toulouse, Toulouse, Toulouse, France, 17Service de Néphrologie, Hôpital Henri-Mondor, Créteil, Créteil, France, 18CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, 19Service de Médecine Interne et Maladies Infectieuses, CHU de Bordeaux, Pessac, France, 20Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, 21National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France

    Background/Purpose: Remission of ANCA-associated vasculitides (AAVs) can be induced with combined glucocorticoids and cyclophosphamide or rituximab (RTX) with comparable efficacy.1 RTX superiority to azathioprine was…
  • Abstract Number: 1955 • 2016 ACR/ARHP Annual Meeting

    Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months

    Benjamin Terrier1, Christian Pagnoux2, Elodie Perrodeau3, Alexandre Karras4, Chahéra Khouatra5, Olivier Aumaître6, Pascal Cohen7, Francois Maurier8, Olivier Decaux9, Hélène Desmurs-Clavel10, Pierre Gobert11, Thomas Quémeneur12, Claire Blanchard-Delaunay13, Pascal Godmer14, Xavier Puéchal15, Luc Mouthon15, Philippe Ravaud16 and Loïc Guillevin15, 1National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 2Mount Sinai Hospital, Toronto, ON, Canada, 3Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 4Nephrology, HEGP, Paris, France, 5CHU Lyon, Lyon, France, 6CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, 7Internal Medicine, Cochin Hospital, Paris, France, 8Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, 9Department of Internal Medicine, Rennes University Hospital, Rennes, France, 10Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, 11Nephrology, Centre Hospitalier d'Avignon, Avignon, France, 12Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, 13Internal Medicine, Centre Hospitalier, Niort, France, 14CH Vannes, Vannes, France, 15Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, 16Hôpital Hôtel Dieu, Paris, France

    Background/Purpose: The previously reported prospective, randomizedÐcontrolled MAINRITSAN trial compared rituximab (RTX) to azathioprine (AZA) for maintenance of ANCA-associated vasculitis (AAV) remissions obtained with a combined…
  • Abstract Number: 2079 • 2016 ACR/ARHP Annual Meeting

    Incidence and Risk of Pneumocystis Jirovecii Pneumonia Following Rituximab Treatment in Granulomatosis with Polyangiitis in the United States: An Analysis from a National Database

    Sirada Panupattanapong1, Anthony R. French2, Andrew J. White2, Margaret A. Olsen3, Maya Rendulic4 and Mary E. Hartman5, 1Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, 2Division of Pediatric Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, 3Division of Infectious Disease, Washington University School of Medicine, St. Louis, MO, 4Center for Administrative Data Research, Washington University School of Medicine, St. Louis, MO, 5Division of Pediatric Critical Care Medicine, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO

    Background/Purpose: Pneumocystis Jirovecii pneumonia (PJP) is a life-threatening complication in granulomatosis with polyangiitis (GPA). Guidelines from EULAR for ANCA-associated vasculitis (AAV) recommend institution of PJP…
  • Abstract Number: 1913 • 2016 ACR/ARHP Annual Meeting

    B Cell Depletion Therapy Impact CD8 T Cells in ANCA-Associated Vasculitis

    Antoine Néel1,2, Marie Bucchia3, Aurelie Caristan1, Mélanie Néel2, Marie Rimbert4, Christian Agard1, Maryvonne Hourmant5, Gaelle Tilly2, Michelle Yap2, François Perrin1, Pascal Godmer6, Julie Graveleau1, Sophie Brouard2, Celine Bressollette7, Fadi Fakhouri8, Mohamed Hamidou9 and Nicolas Degauque2, 1Internal Medicine Department, Nantes University Hospital, Nantes, France, 2INSERM U1064, Nantes, France, 3Pediatrics, Nantes University Hospital, Nantes, France, 4Immunology Laboratory, Nantes University Hospital, Nantes, France, 5Nephrology, Nantes University Hospital, Nantes, France, 6CH Vannes, Vannes, France, 7Virology Laboratory, Nantes University Hospital, Nantes, France, 8Nephrology Department, Nantes University Hospital, Nantes, France, 9Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France

    Background/Purpose: In anti-neutrophil cytoplasmic antibodies associated vasculitis (AAV), several clues suggest that the efficacy of B cell depletion therapy lies beyond the suppression of ANCA-producing…
  • Abstract Number: 1930 • 2016 ACR/ARHP Annual Meeting

    Factors Associated with Glucocorticoid Exposure in ANCA-Associated Vasculitis

    Matthew D. Cascino1, Ulrich Specks2, Peter A. Merkel3, Philip Seo4, Robert F. Spiera5, Carol A. Langford6, Gary S. Hoffman6, Cees G.M. Kallenberg7, E. William St Clair8, Paul A. Monach9, John H. Stone10 and Paul Brunetta11, 1Division of Rheumatology, University of California, San Francisco, San Francisco, CA, 2Mayo Clinic, Rochester, MN, 3Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 4Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 5Rheumatology, Hospital for Special Surgery, New York, NY, 6Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 7Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 8Rheumatology, Duke University Medical Center, Durham, NC, 9Rheumatology, Boston University School of Medicine, Boston, MA, 10Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 11Genentech, Inc., South San Francisco, CA

    Background/Purpose: Factors associated with cumulative glucocorticoid exposure in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) have not previously been described. We examined the association…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology